Amneal Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors bought 2,563 call options on the stock. This represents an increase of approximately 719% compared to the average daily volume of 313 call options.

Insider Activity

In other news, SVP Jason B. Daly sold 43,657 shares of the company's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the transaction, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. This represents a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 17.46% of the company's stock.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rothschild Investment LLC purchased a new stake in Amneal Pharmaceuticals in the 2nd quarter worth approximately $26,000. Gladius Capital Management LP acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $37,000. DekaBank Deutsche Girozentrale purchased a new stake in Amneal Pharmaceuticals during the second quarter worth $42,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals during the second quarter valued at $62,000. Finally, Xponance Inc. purchased a new position in Amneal Pharmaceuticals in the second quarter valued at $65,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday. Piper Sandler increased their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, November 11th. Finally, Truist Financial lifted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Amneal Pharmaceuticals Trading Up 0.1 %

AMRX traded up $0.01 during midday trading on Monday, hitting $7.79. 604,667 shares of the company were exchanged, compared to its average volume of 1,379,067. The company's 50 day simple moving average is $8.42 and its 200 day simple moving average is $7.95. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -11.46 and a beta of 1.12. Amneal Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $9.48.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.